Viewing Siglecs through the lens of tumor immunology

Immunological Reviews

Volumn 276, Issue 1, 2017, Pages 178-191

  Fraschilla, Isabella ^a   Pillai, Shiv ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cancer tumor immunology; hypersialylation; immune evasion; immune regulation; inhibitory receptor; sialic acid; Siglec

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD22 ANTIGEN; SIALOADHESIN; DIFFERENTIATION ANTIGEN; LECTIN; LEUKOCYTE ANTIGEN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIGLEC1 PROTEIN, HUMAN; SIGLEC7 PROTEIN, HUMAN; SIGLEC9 PROTEIN, HUMAN;

EXOSOME; FACILITATION; HUMAN; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIALYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; ADAPTIVE IMMUNITY; ANIMAL; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; NEUTROPHIL; PROCEDURES; TUMOR ESCAPE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LECTINS; NEOPLASMS; NEUTROPHILS; SIALIC ACID BINDING IG-LIKE LECTIN 1; SIALIC ACID BINDING IMMUNOGLOBULIN-LIKE LECTINS; TUMOR ESCAPE;

EID: 85014353929     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12526     Document Type: Review

References (133)

1. Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol. 2009;19:507–514.
2. Varki A, Schauer R. Sialic Acids, In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GR, Etzler ME, eds. Essentials of Glycobiology, Chapter 14. Cold Spring Harbor, NY: Cold Spring Harbor Press; 2009:199–218.
3. Varki A. Multiple changes in sialic acid biology during human evolution. Glycoconj J. 2009;26:231–245.
4. Pillai S, Netravali IA, Cariappa A, Mattoo H. Siglecs and immune regulation. Annu Rev Immunol. 2012;30:357–392.
5. Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014;14:653–666.
6. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996;56:5309–5318.
7. Pearce OMT, Läubli H. Sialic acids in cancer biology and immunity. Glycobiology. 2016;26:111–128.
8. Tangvoranuntakul P, Gagneux P, Diaz S, et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA. 2003;100:12045–12050.
9. Hedlund M, Padler-Karavani V, Varki NM, Varki A. Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. Proc Natl Acad Sci USA. 2008;105:18936–18941.
10. Varki A, Kannagi R, Toole BP. Glycosylation changes in cancer. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GR, Etzler ME, eds. Essentials of Glycobiology, Chapter 44. Cold Spring Harbor, NY: Cold Spring Harbor Press; 2009:617–632.
11. Swindall AF, Londoño-Joshi AI, Schultz MJ, Fineberg N, Buchsbaum DJ, Bellis SL. ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines. Cancer Res. 2013;73:2368–2378.
12. Angata T, Varki A. Siglec-7: A sialic acid-binding lectin of the immunoglobulin superfamily. Glycobiology. 2000;10:431–438.
13. Falco M, Biassoni R, Bottino C, et al. Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. J Exp Med. 1999;190:793–802.
14. Angata T, Varki A. Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways. J Biol Chem. 2000;275:22127–22135.
15. Zhang JQ, Nicoll G, Jones C, Crocker PR. Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. J Biol Chem. 2000;275:22121–22126.
16. Nicoll G, Ni J, Liu D, et al. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J Biol Chem. 1999;274:34089–34095.
17. Lock K, Zhang J, Lu J, Lee SH, Crocker PR. Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells. Immunobiology. 2004;209:199–207.
18. Nguyen DH, Ball ED, Varki A. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs. Exp Hematol. 2006;34:728–735.
19. Miyazaki K, Sakuma K, Kawamura YI, et al. Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and -9. J Immunol. 2012;188:4690–4700.
20. Zhang JQ, Biedermann B, Nitschke L, Crocker PR. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol. 2004;34:1175–1184.
21. Avril T, Floyd H, Lopez F, Vivier E, Crocker PR. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J Immunol. 2004;173:6841–6849.
22. Yamaji T, Mitsuki M, Teranishi T, Hashimoto Y. Characterization of inhibitory signaling motifs of the natural killer cell receptor Siglec-7: Attenuated recruitment of phosphatases by the receptor is attributed to two amino acids in the motifs. Glycobiology. 2005;15:667–676.
23. Ikehara Y, Ikehara SK, Paulson JC. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem. 2004;279:43117–43125.
24. von Gunten S, Yousefi S, Seitz M, et al. Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood. 2005;106:1423–1431.
25. Mitsuki M, Nara K, Yamaji T, et al. Siglec-7 mediates nonapoptotic cell death independently of its immunoreceptor tyrosine-based inhibitory motifs in monocytic cell line U937. Glycobiology. 2010;20:395–402.
26. Biedermann B, Gil D, Bowen DT, Crocker PR. Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors. Leuk Res. 2007;31:211–220.
27. Nicoll G, Avril T, Lock K, Furukawa K, Bovin N, Crocker PR. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. Eur J Immunol. 2003;33:1642–1648.
28. Ito A, Handa K, Withers DA, Satoh M, Hakomori S. Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: Possible role of disialogangliosides in tumor progression. FEBS Lett. 2001;498:116–120.
29. Miyazaki K, Ohmori K, Izawa M, et al. Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers. Cancer Res. 2004;64:4498–4505.
30. Yamaji T, Teranishi T, Alphey MS, Crocker PR, Hashimoto Y. A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues. A comparison with Siglec-9. J Biol Chem. 2002;277:6324–6332.
31. Urmacher C, Cordon-Cardo C, Houghton AN. Tissue distribution of GD3 ganglioside detected by mouse monoclonal antibody R24. Am J Dermatopathol. 1989;11:577–581.
32. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med. 1982;155:1133–1147.
33. Läubli H, Pearce OMT, Schwarz F, et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci USA. 2014;111:14211–14216.
34. Läubli H, Alisson-Silva F, Stanczak MA, et al. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. J Biol Chem. 2014;289:33481–33491.
35. Vitale C, Romagnani C, Falco M, et al. Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proc Natl Acad Sci USA. 1999;96:15091–15096.
36. Sabit I, Hashimoto N, Matsumoto Y, Yamaji T, Furukawa K, Furukawa K. Binding of a sialic acid-recognizing lectin Siglec-9 modulates adhesion dynamics of cancer cells via calpain-mediated protein degradation. J Biol Chem. 2013;288:35417–35427.
37. Tanida S, Akita K, Ishida A, et al. Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of β-catenin and subsequent cell growth. J Biol Chem. 2013;288:31842–31852.
38. Ohta M, Ishida A, Toda M, et al. Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9. Biochem Biophys Res Commun. 2010;402:663–669.
39. Rughetti A, Pellicciotta I, Biffoni M, et al. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol. 2005;174:7764–7772.
40. Ando M, Tu W, Nishijima K-I, Iijima S. Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs. Biochem Biophys Res Commun. 2008;369:878–883.
41. Varchetta S, Brunetta E, Roberto A, et al. Engagement of Siglec-7 receptor induces a pro-inflammatory response selectively in monocytes. PLoS ONE. 2012;7:e45821.
42. Morvan MG, Lanier LL. NK cells and cancer: You can teach innate cells new tricks. Nat Rev Cancer. 2016;16:7–19.
43. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27:5932–5943.
44. Jandus C, Boligan KF, Chijioke O, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest. 2014;124:1810–1820.
45. Saito S, Orikasa S, Satoh M, Ohyama C, Ito A, Takahashi T. Expression of globo-series gangliosides in human renal cell carcinoma. Jpn J Cancer Res. 1997;88:652–659.
46. Kawasaki Y, Ito A, Withers DA, et al. Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells. Glycobiology. 2010;20:1373–1379.
47. Belisle JA, Horibata S, Jennifer GAA, et al. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer. 2010;9:118.
48. Gubbels JAA, Felder M, Horibata S, et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer. 2010;9:11.
49. Patankar MS, Jing Y, Morrison JC, et al. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol. 2005;99:704–713.
50. Hudak JE, Canham SM, Bertozzi CR. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol. 2014;10:69–75.
51. Avril T, North SJ, Haslam SM, Willison HJ, Crocker PR. Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2,8-sialyltransferase gene expression. J Leukoc Biol. 2006;80:787–796.
52. Jacobs R, Hintzen G, Kemper A, et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol. 2001;31:3121–3127.
53. Crocker PR, Werb Z, Gordon S, Bainton DF. Ultrastructural localization of a macrophage-restricted sialic acid binding hemagglutinin, SER, in macrophage-hematopoietic cell clusters. Blood. 1990;76:1131–1138.
54. Crocker PR, Kelm S, Dubois C, et al. Purification and properties of sialoadhesin, a sialic acid-binding receptor of murine tissue macrophages. EMBO J. 1991;10:1661–1669.
55. Crocker PR, Gordon S. Mouse macrophage hemagglutinin (sheep erythrocyte receptor) with specificity for sialylated glycoconjugates characterized by a monoclonal antibody. J Exp Med. 1989;169:1333–1346.
56. Hartnell A, Steel J, Turley H, Jones M, Jackson DG, Crocker PR. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood. 2001;97:288–296.
57. Crocker PR, Mucklow S, Bouckson V, et al. Sialoadhesin, a macrophage sialic acid binding receptor for haemopoietic cells with 17 immunoglobulin-like domains. EMBO J. 1994;13:4490–4503.
58. Munday J, Floyd H, Crocker PR. Sialic acid binding receptors (siglecs) expressed by macrophages. J Leukoc Biol. 1999;66:705–711.
59. Delputte PL, Van Gorp H, Favoreel HW, et al. Porcine sialoadhesin (CD169/Siglec-1) is an endocytic receptor that allows targeted delivery of toxins and antigens to macrophages. PLoS ONE. 2011;6:e16827.
60. Jones C, Virji M, Crocker PR. Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake. Mol Microbiol. 2003;49:1213–1225.
61. van den Berg TK, Brevé JJ, Damoiseaux JG, et al. Sialoadhesin on macrophages: Its identification as a lymphocyte adhesion molecule. J Exp Med. 1992;176:647–655.
62. Nath D, Hartnell A, Happerfield L, et al. Macrophage-tumour cell interactions: Identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology. 1999;98:213–219.
63. Ohnishi K, Komohara Y, Saito Y, et al. CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma. Cancer Sci. 2013;104:1237–1244.
64. Ohnishi K, Yamaguchi M, Erdenebaatar C, et al. Prognostic significance of CD169-positive lymph node sinus macrophages in patients with endometrial carcinoma. Cancer Sci. 2016;107:846–852.
65. + lymph node sinus macrophages in patients with malignant melanoma. Cancer Immunol Res. 2015;3:1356–1363.
66. Zhang Y, Li J-Q, Jiang Z-Z, Li L, Wu Y, Zheng L. CD169 identifies an anti-tumour macrophage subpopulation in human hepatocellular carcinoma. J Pathol. 2016;239:231–241.
67. Pino M, Erkizia I, Benet S, et al. HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells. Retrovirology. 2015;12:37.
68. Erikson E, Wratil PR, Frank M, et al. Mouse Siglec-1 mediates trans-infection of surface-bound murine leukemia virus in a sialic acid N-Acyl side chain-dependent manner. J Biol Chem. 2015;290:27345–27359.
69. Rempel H, Calosing C, Sun B, Pulliam L. Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. PLoS ONE. 2008;3:e1967.
70. Oetke C, Vinson MC, Jones C, Crocker PR. Sialoadhesin-deficient mice exhibit subtle changes in B- and T-cell populations and reduced immunoglobulin M levels. Mol Cell Biol. 2006;26:1549–1557.
71. + T lymphocyte homeostasis by modulating O-glycan biosynthesis. Immunity. 2000;12:273–283.
72. − T cells with a distinct activation and glycosylation profile. J Immunol. 2013;190:2593–2602.
73. Chen WC, Kawasaki N, Nycholat CM, et al. Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169. PLoS ONE. 2012;7:e39039.
74. van den Berg TK, Nath D, Ziltener HJ, et al. Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1). J Immunol. 2001;166:3637–3640.
75. Kawasaki N, Vela JL, Nycholat CM, et al. Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation. Proc Natl Acad Sci USA. 2013;110:7826–7831.
76. Sewald X, Ladinsky MS, Uchil PD, et al. Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infection. Science. 2015;350:563–567.
77. Jobe O, Trinh HV, Kim J, et al. Effect of cytokines on Siglec-1 and HIV-1 entry in monocyte-derived macrophages: The importance of HIV-1 envelope V1V2 region. J Leukoc Biol. 2016;99:1089–1106.
78. Klaas M, Crocker PR. Sialoadhesin in recognition of self and non-self. Semin Immunopathol. 2012;34:353–364.
79. Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–289.
80. Tkach M, Théry C. Communication by extracellular vesicles: Where we are and where we need to go. Cell. 2016;164:1226–1232.
81. Saunderson SC, Dunn AC, Crocker PR, McLellan AD. CD169 mediates the capture of exosomes in spleen and lymph node. Blood. 2014;123:208–216.
82. Black LV, Saunderson SC, Coutinho FP, et al. The CD169 sialoadhesin molecule mediates cytotoxic T-cell responses to tumour apoptotic vesicles. Immunol Cell Biol. 2016;94:430–438.
83. Pucci F, Garris C, Lai CP, et al. SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science. 2016;352:242–246.
84. Lu H, Goodell C, Disis ML. Humoral Immunity against tumor -associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res. 2008;7:1388–1394.
85. Scanlan MJ, Chen YT, Williamson B, et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer. 1998;76:652–658.
86. Asano K, Nabeyama A, Miyake Y, et al. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity. 2011;34:85–95.
87. Pezzutto A, Dörken B, Moldenhauer G, Clark EA. Amplification of human B cell activation by a monoclonal antibody to the B cell-specific antigen CD22, Bp 130/140. J Immunol. 1987;138:98–103.
88. Wilson GL, Fox CH, Fauci AS, Kehrl JH. cDNA cloning of the B cell membrane protein CD22: A mediator of B-B cell interactions. J Exp Med. 1991;173:137–146.
89. Torres RM, Law CL, Santos-Argumedo L, et al. Identification and characterization of the murine homologue of CD22, a B lymphocyte-restricted adhesion molecule. J Immunol. 1992;149:2641–2649.
90. Muta T, Kurosaki T, Misulovin Z, Sanchez M, Nussenzweig MC, Ravetch JV. A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature. 1994;369:340.
91. D'Ambrosio D, Hippen KL, Minskoff SA, et al. Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1. Science. 1995;268:293–297.
92. Schulte RJ, Campbell MA, Fischer WH, Sefton BM. Tyrosine phosphorylation of CD22 during B cell activation. Science. 1992;258:1001–1004.
93. Leprince C, Draves KE, Geahlen RL, Ledbetter JA, Clark EA. CD22 associates with the human surface IgM-B-cell antigen receptor complex. Proc Natl Acad Sci USA. 1993;90:3236–3240.
94. Peaker CJ, Neuberger MS. Association of CD22 with the B cell antigen receptor. Eur J Immunol. 1993;23:1358–1363.
95. Doody GM, Justement LB, Delibrias CC, et al. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science. 1995;269:242–244.
96. Campbell MA, Klinman NR. Phosphotyrosine-dependent association between CD22 and protein tyrosine phosphatase 1C. Eur J Immunol. 1995;25:1573–1579.
97. Law CL, Sidorenko SP, Chandran KA, et al. CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation. J Exp Med. 1996;183:547–560.
98. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Hyperresponsive B cells in CD22-deficient mice. Science. 1996;274:798–801.
99. Sato S, Miller AS, Inaoki M, et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: Altered signaling in CD22-deficient mice. Immunity. 1996;5:551–562.
100. Pezzutto A, Rabinovitch PS, Dörken B, Moldenhauer G, Clark EA. Role of the CD22 human B cell antigen in B cell triggering by anti-immunoglobulin. J Immunol. 1988;140:1791–1795.
101. Nitschke L, Carsetti R, Ocker B, Köhler G, Lamers MC. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol. 1997;7:133–143.
102. Otipoby KL, Draves KE, Clark EA. CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1. J Biol Chem. 2001;276:44315–44322.
103. Smith KG, Tarlinton DM, Doody GM, Hibbs ML, Fearon DT. Inhibition of the B cell by CD22: A requirement for Lyn. J Exp Med. 1998;187:807–811.
104. Chan VW, Lowell CA, DeFranco AL. Defective negative regulation of antigen receptor signaling in Lyn-deficient B lymphocytes. Curr Biol. 1998;8:545–553.
105. Cornall RJ, Cyster JG, Hibbs ML, et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity. 1998;8:497–508.
106. Aruffo A, Kanner SB, Sgroi D, Ledbetter JA, Stamenkovic I. CD22-mediated stimulation of T cells regulates T-cell receptor/CD3-induced signaling. Proc Natl Acad Sci USA. 1992;89:10242–10246.
107. Sjoberg ER, Powell LD, Klein A, Varki A. Natural ligands of the B cell adhesion molecule CD22 beta can be masked by 9-O-acetylation of sialic acids. J Cell Biol. 1994;126:549–562.
108. Sgroi D, Varki A, Braesch-Andersen S, Stamenkovic I. CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. J Biol Chem. 1993;268:7011–7018.
109. Powell LD, Sgroi D, Sjoberg ER, Stamenkovic I, Varki A. Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition. J Biol Chem. 1993;268:7019–7027.
110. van der Merwe PA, Crocker PR, Vinson M, Barclay AN, Schauer R, Kelm S. Localization of the putative sialic acid-binding site on the immunoglobulin superfamily cell-surface molecule CD22. J Biol Chem. 1996;271:9273–9280.
111. Sgroi D, Nocks A, Stamenkovic I. A single N-linked glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CD33. J Biol Chem. 1996;271:18803–18809.
112. Hanasaki K, Varki A, Powell LD. CD22-mediated cell adhesion to cytokine-activated human endothelial cells. Positive and negative regulation by alpha 2-6-sialylation of cellular glycoproteins. J Biol Chem. 1995;270:7533–7542.
113. Braesch-Andersen S, Stamenkovic I. Sialylation of the B lymphocyte molecule CD22 by alpha 2,6-sialyltransferase is implicated in the regulation of CD22-mediated adhesion. J Biol Chem. 1994;269:11783–11786.
114. Tuscano J, Engel P, Tedder TF, Kehrl JH. Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation. Blood. 1996;87:4723–4730.
115. Shan D, Press OW. Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol. 1995;154:4466–4475.
116. Engel P, Nojima Y, Rothstein D, et al. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. J Immunol. 1993;150:4719–4732.
117. Stamenkovic I, Seed B. The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion. Nature. 1990;345:74–77.
118. Nitschke L, Floyd H, Ferguson DJ, Crocker PR. Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells. J Exp Med. 1999;189:1513–1518.
119. Floyd H, Nitschke L, Crocker PR. A novel subset of murine B cells that expresses unmasked forms of CD22 is enriched in the bone marrow: Implications for B-cell homing to the bone marrow. Immunology. 2000;101:342–347.
120. O'Keefe TL, Williams GT, Batista FD, Neuberger MS. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med. 1999;189:1307–1313.
121. Andreu P, Johansson M, Affara NI, et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell. 2010;17:121–134.
122. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005;7:411.
123. Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov. 2012;11:311–331.
124. Yuen GJ, Demissie E, Pillai S. B lymphocytes and Cancer: A love-hate relationship. Trends Cancer. 2016;2:747–757.
125. Jabbour E, O'Brien S, Ravandi F, Kantarjian H. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015;125:4010–4016.
126. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–753.
127. Daniels MA, Hogquist KA, Jameson SC. Sweet “n” sour: The impact of differential glycosylation on T cell responses. Nat Immunol. 2002;3:903–910.
128. Perdicchio M, Ilarregui JM, Verstege MI, et al. Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells. Proc Natl Acad Sci USA. 2016;113:3329–3334.
129. Redelinghuys P, Antonopoulos A, Liu Y, et al. Early murine T-lymphocyte activation is accompanied by a switch from N-Glycolyl- to N-acetyl-neuraminic acid and generation of ligands for siglec-E. J Biol Chem. 2011;286:34522–34532.
130. Takagi H, Fukaya T, Eizumi K, et al. Plasmacytoid dendritic cells are crucial for the initiation of inflammation and T cell immunity in vivo. Immunity. 2011;35:958–971.
131. Bandala-Sanchez E, Zhang Y, Reinwald S, et al. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat Immunol. 2013;14:741–748.
132. Welte K, Miller G, Chapman PB, et al. Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J Immunol. 1987;139:1763–1771.
133. Wu C, Rauch U, Korpos E, et al. Sialoadhesin-positive macrophages bind regulatory T cells, negatively controlling their expansion and autoimmune disease progression. J Immunol. 2009;182:6508–6516.